TrialPath
Recruiting

Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

NCT07817251 · Novo Nordisk A/S
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Safety And Tolerability of 3 Switch Regimens From Semaglutide 1.0 mg and 2.0 mg to Co-Administered Cagrilintide and Semaglutide (Cagrisema) in Participants With Type 2 Diabetes
About this study
The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.
Eligibility criteria
Inclusion criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Diagnosed with type 2 diabetes mellitus (T2DM) greater than or equal to (≥) 180 days before screening. * Stable once-weekly dose ≥ 90 days before screening of branded s.c. semaglutide. Branded semaglutide s.c. includes Ozempic and Wegovy. Participants on compounded semaglutide are ineligible. * Not on treatment with oral antidiabetic drugs or on stable daily dose(s) ≥ 90 days before screening of any of the following antidiabetic drug(s) or combination regimen at effective or maximum tolerated dose (MTD) as judged by the investigator: metformin and/or sodiumglucose co-transporter-2 (SGLT2) inhibitor. * Glycated haemoglobin (HbA1c) 6.5-10.5 percentage (%) (48-91 millimoles per mole \[mmol/mol\]) (both inclusive) as determined by central laboratory at screening. * Body mass index (BMI) ≥ 25 kilograms per square meter (kg/m\^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening. Exclusion criteria: * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method from screening. * Renal impairment with estimated glomerular filtration rate (eGFR) less than (\<) 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2) as determined by central laboratory at screening. * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * A self-reported change in body weight \> 5% within 90 days before screening irrespective of medical records. * Use of personal continuous glucose monitoring (CGM) devices. Participants currently using personal CGM devices must discontinue use prior to screening and throughout study participation.
Study design
Enrollment target: 210 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-09-16
Estimated completion: 2027-07-21
Last updated: 2026-09-30
Interventions
Drug: CagriSema
Primary outcomes
  • • Number of treatment emergent adverse events (TEAEs) (From baseline (Week 0) to end of treatment (Week 16))
Sponsor
Novo Nordisk A/S · industry
Contacts & investigators
ContactNovo Nordisk · contact · clinicaltrials@novonordisk.com · (+1) 866-867-7178
InvestigatorClinical Transparency (dept. 2834) · study_director, Novo Nordisk A/S
All locations (40)
Gilbert Center For Family MedicineRecruiting
Gilbert, Arizona, United States
Ark Clinical ResearchRecruiting
Fountain Valley, California, United States
Thrive Clinical Research GroupRecruiting
Glendora, California, United States
Scripps Whittier Diabetes InstRecruiting
La Jolla, California, United States
Downtown LA Res Ctr. Inc.Recruiting
Los Angeles, California, United States
Valley Clinical Trials, Inc.Recruiting
Northridge, California, United States
Dream Team Clinical ResearchRecruiting
Pomona, California, United States
Clinical Trials Research_SacramentoRecruiting
Sacramento, California, United States
Linda Vista Health Care CtrRecruiting
San Diego, California, United States
Chase Medical Research LLCRecruiting
Waterbury, Connecticut, United States
Northeast Research InstituteRecruiting
Fleming Island, Florida, United States
AGA Clinical TrialRecruiting
Hialeah, Florida, United States
Adult Medicine of Lake County, IncRecruiting
Mt. Dora, Florida, United States
Optimal Research SitesRecruiting
Orange City, Florida, United States
Metabolic Research Institute IncRecruiting
West Palm Beach, Florida, United States
East West Med Res InstRecruiting
Honolulu, Hawaii, United States
Endeavor HealthRecruiting
Skokie, Illinois, United States
Iowa Diabetes & Endo Res CtrRecruiting
West Des Moines, Iowa, United States
Alliance for Multispecialty ResearchRecruiting
Newton, Kansas, United States
Cotton O'Neil Diabetes & EndocrinologyRecruiting
Topeka, Kansas, United States
Northern Pines Hlth Ctr, PCRecruiting
Buckley, Michigan, United States
Palm Research Center Inc-VegasRecruiting
Las Vegas, Nevada, United States
Albuquerque Clinical Trials Inc.Recruiting
Albuquerque, New Mexico, United States
PharmQuest Life Sciences LLCRecruiting
Greensboro, North Carolina, United States
Accellacare WilmingtonRecruiting
Wilmington, North Carolina, United States
Advanced Medical ResearchNot Yet Recruiting
Maumee, Ohio, United States
Clinical Research AssociatesRecruiting
Nashville, Tennessee, United States
Amarillo Med Spec LLPRecruiting
Amarillo, Texas, United States
Texas Diabetes & EndocrinologyRecruiting
Austin, Texas, United States
North Texas Endocrine CenterRecruiting
Dallas, Texas, United States
Diabetes and Thyroid Center of Fort WorthRecruiting
Fort Worth, Texas, United States
JCCT- Juno NW HoustonRecruiting
Houston, Texas, United States
Sante Clinical ResearchRecruiting
Kerrville, Texas, United States
DCOL Ctr for Clin ResRecruiting
Longview, Texas, United States
North Hills Medical Research IncRecruiting
North Richland Hills, Texas, United States
NE Clin Res of San AntonioNot Yet Recruiting
San Antonio, Texas, United States
J.Lewis Research IncRecruiting
Salt Lake City, Utah, United States
Diabetes & Endo Treatment SpecNot Yet Recruiting
Sandy City, Utah, United States
Chrysalis Clinical ResearchRecruiting
St. George, Utah, United States
Tidewater Physicians Multispecialty GroupRecruiting
Newport News, Virginia, United States
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema · TrialPath